The Efficacy of Sodium Channel Blockers to Prevent Phencyclidine-Induced Cognitive Dysfunction in the Rat: Potential for Novel Treatments for Schizophrenia

Charles H. Large, Silvia Bison, Ilaria Sartori, Kevin D. Read,1 Alessandro Gozzi,2 Davide Quarta, Marinella Antolini, Emma Hollands, Catherine H. Gill, Martin J. Gunthorpe, Nagi Idris, Jo C. Neill, and Giuseppe S. Alvaro


Received January 19, 2011; accepted April 07, 2011

ABSTRACT

Sodium channel inhibition is a well-precedented mechanism used to treat epilepsy and other hyperexcitability disorders. The established sodium channel blocker and broad-spectrum anticonvulsant lamotrigine is also effective in the treatment of bipolar disorder and has been evaluated in patients with schizophrenia. Double-blind placebo-controlled clinical trials found that the drug has potential to reduce cognitive symptoms of the disorder. However, because of compound-related side-effects and the need for dose titration, a conclusive evaluation of the drug’s efficacy in patients with schizophrenia has not been possible. (5R)-5-(4-[(2-fluorophenyl)methyl]oxy)phenyl)-7-methyl-1,7-diazaspiro[4.4]nonan-6-one (GSK2) and (2R,5R)-2-(4-[(2-fluorophenyl)methyl]oxy)phenyl)-7-methyl-1,7-diazaspiro[4.4]nonan-6-one (GSK3) are two new structurally diverse sodium channel blockers with potent anticonvulsant activity. In this series of studies in the rat, we compared the efficacy of the two new molecules to prevent a cognitive deficit induced by the N-methyl-D-aspartic acid receptor antagonist phencyclidine (PCP) in the reversal-learning paradigm in the rat. We also explored the effects of the drugs to prevent brain activation and neurochemical effects of PCP. We found that, like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication.

Introduction

Improved treatment for patients with schizophrenia requires either that we identify the genetic or molecular basis for the illness or that we progress drugs with different mechanisms of action into patients to evaluate their efficacy in an empirical manner. This latter approach is facilitated by the use of models in which “psychosis” is induced by administration of NMDA receptor antagonists, such as ketamine or PCP in humans (Krystal et al., 2002) or rodents (Large, 2007; Neill et al., 2010). These models are sensitive to atypical antipsychotic drugs. Lamotrigine, a voltage-gated sodium channel blocker that has broad-spectrum anticonvulsant efficacy and that is used in the treatment of bipolar disorder, has also been shown to reduce NMDA receptor antagonist-induced psychotic symptoms in both humans (Anand et al., 2000; Deakin et al., 2008) and rodents (Brodly et al., 2003; Idris et al., 2005; Gozzi et al., 2008a; Hunt et al., 2008). These findings supported the proposition that the drug might be used in the treatment of schizophrenia, but further studies in patients are needed to evaluate their efficacy in an empirical manner.

ABBREVIATIONS: NMDA, N-methyl-D-aspartic acid; PCP, phencyclidine; CNS, central nervous system; DMSO, dimethyl sulfoxide; ANOVA, analysis of variance; MAO, monoamine oxidase; pHMRI, pharmacological magnetic resonance imaging; MRI, magnetic resonance imaging; RARE, rapid acquisition with refocused echoes; GSK2, (5R)-5-(4-[(2-fluorophenyl)methyl]oxy)phenyl)-L-prolinamide; GSK3, (2R,5R)-2-(4-[(2-fluorophenyl)methyl]oxy)phenyl)-7-methyl-1,7-diazaspiro[4.4]nonan-6-one; rCBV, relative cerebral blood volume; HPMC, hydroxypropyl-methylcellulose; VOI, volume of interest; mPFC, medial prefrontal cortex; 5-HT, serotonin; NA, noradrenaline; DA, dopamine; GPP39653, (S)-2-amino-4-propyl-6-phosphono-3-pentenoic acid.
useful in the treatment of schizophrenia (Large et al., 2005), a hypothesis that was also strongly supported by positive results from several small clinical trials of lamotrigine added on to atypical antipsychotic drugs in patients with treatment-resistant schizophrenia (Dursun et al., 1999; Dursun and Deakin, 2001; Tiilinen et al., 2003; Kremer et al., 2004). Subsequently, two larger 12-week, double-blind placebo controlled trials with add-on lamotrigine failed to demonstrate efficacy on their primary endpoint (change in the Positive and Negative Symptom Scale) but did find evidence for improvement in cognitive symptoms (Goff et al., 2007). Consistent cognitive benefit has previously been attributed to lamotrigine in patients with epilepsy (Aldenkamp and Baker, 2001). A large placebo response in the schizophrenia trials may have compromised their overall sensitivity, and the need for a 6-week dose titration with lamotrigine to lower the risk of rash may also have reduced the likelihood of separating from placebo over the relatively short trial period. However, given the promise of efficacy of lamotrigine versus cognitive deficits in schizophrenia, which represent a major unmet need in the management of these patients, it has remained a key challenge to identify novel, structurally diverse compounds with a similar pharmacology that might be progressed into the clinic for this indication.

As argued previously (Xie and Hagan, 1998; Large et al., 2005, 2009a), the primary mechanism of action of lamotrigine is likely to be the use-dependent inhibition of voltage-gated sodium channels. However, it cannot be ruled out that other molecular interactions, such as inhibition of voltage-gated N-type (Cav2.2) calcium channels (Cunningham and Jones, 2000) and inhibition of monoamine oxidase B (Southam et al., 2005), are possibly therapeutically relevant. We have developed two novel use-dependent sodium channel blockers, (5R)-5-4-([(2-fluorophenyl)methyl]oxy)phenyl)-1-prolinamide (GSK2) and (2R,5R)-2-4-([(2-fluorophenyl)methyl]oxy)phenyl)-7-methyl-1,7-diazaspiro[4.4]nonan-6-one (GSK3). Like lamotrigine, the two compounds are effective anticonvulsant agents in animal models of seizure, but have notably higher affinities for the NMDA receptor and is unaffected by the potent ability of GSK2 to inhibit monoamine oxidase B. These drugs show promise as new tools to explore the efficacy of sodium channel blockers in patients with schizophrenia.

**Materials and Methods**

**Reversal Learning**

**Subjects.** Eighty female hooded-Lister rats (Harlan UK Limited, Bicester, Oxon, UK) were used as subjects for the present studies. Rats were housed in groups of four to five under standard laboratory conditions and a 12-h light/dark cycle, lights on at 7:00 AM. Testing was carried out in the light phase. Before operant training and testing, rats were gradually food deprived to approximately 90% of free-feeding body weight (225-250 g); reduced body weight was maintained by restricting the amount of food per day (standard laboratory chow, Special Diet Services, Essex, UK) given to each rat (12 g/day). The availability of water was not restricted. Rats were aged 12 weeks at the start of training in the reversal-learning paradigm and were 24 weeks old when the first drug treatment was given. Experiments were conducted in accordance with the Animals Scientific Procedures Act, UK, 1986, and approved by the University of Bradford ethical review process.

**Drugs.** GSK2 was dissolved in 0.5% methylcellulose/2% DMSO. GSK2 was administered orally and was given 45 min before testing and 15 min before treatment with PCP. GSK3 was dissolved in saline and administered orally 90 min before testing and 60 min before treatment with PCP. Lamotrigine was dissolved in 0.5% methylcellulose and was administered via the intraperitoneal route and given 90 min before testing and 60 min before treatment with PCP. PCP HCl (Sigma, UK) was dissolved in saline and administered intraperitoneally 30 min before testing. In all experiments, the appropriate vehicle treatment was used. All doses are quoted as base-equivalent weight.

**Procedure.** Training. Rats were trained and tested in the reversal-learning paradigm as described previously (Idris et al., 2005). All rats were tested in one of eight operant chambers (constructed in-house) controlled by Med-PC software (version 2.0 for DOS or Med-PC for Windows; Med Associates, Inc. Lafayette, IN). After habituation to the operant chambers, rats were trained to respond for food on a fixed ratio 1 (FR1) schedule of reinforcement with both levers active. When responding stabilized, rats were trained to press either the left or right lever for food delivery according to a visual cue (LED on or off). These sessions took approximately 30 min and ended after 128 total responses (correct + incorrect). A criterion of 90% accuracy (≥115 correct responses per session) had to be achieved over at least 3 consecutive days before being trained on the opposite contingency. Approximately 6 weeks of daily training was required before introducing the reversal-learning task.

**Testing.** Each reversal-learning session began with a 5-min period (the initial phase) during which the reinforcement contingency matched that of the previous day’s training session. At the conclusion
of the initial phase, the house light was extinguished and a 2-min time-out began. After the time-out, the house light was illuminated, and the next phase of the task began (the reversal phase), during which the reinforcement contingency was reversed. That is, state of the visual cue (lit or unlit) associated with reinforcement was switched. The predictable nature of the time-out and the break in response requirement act as cues for the contingency change. These aspects of the task provide the advantage of decreasing the time required for training. Several reversal-learning sessions were performed before initiating drug studies to ensure stable performance. A criterion of 75% accuracy had to be achieved over at least 3 consecutive days before drug testing. An additional week was required to perform reversal test sessions before drug testing started.

Experimental Design. Rats were tested on a cycle of 4 days (I dri et al., 2005). On day 1, each animal had a 30-min operant training session. The following day, animals received the appropriate drug(s) and undertook a reversal-learning session. On days 3 and 4, each animal underwent a further operant training session and reversed task session, respectively, to ensure that responding was back to baseline after the drug treatment. The drug treatment given to each rat (and within each home cage) over the course of the seven experiments was randomized. Every effort was made to keep the number of drug and vehicle treatments equivalent among animals and to randomize the order of treatments. The second cohort took part only in the final drug experiment. This second cohort of animals was required to comply with the Animals Scientific Procedures Act (UK, 1986) (i.e., the number of drug treatments each animal can receive is restricted).

Data Analysis. Data from this study are presented as the percentage of correct responses (±S.E.M.), with values for the initial and reversal task presented for the different drug treatment groups. These data were used to determine whether there was a significant effect of drug(s) on response accuracy (e.g., that might reflect cognitive dysfunction); these data were Arc-Sin transformed before analysis. Statistical significance was assumed when p < 0.05 and was determined as follows: a one-way ANOVA was performed to detect a main effect of drug(s) treatment on the initial and reversal tasks. Where a significant effect was detected, a post hoc Dunnett’s test was performed to compare treatment groups versus the appropriate control. Raw lever press data (supplemental tables) were used to determine whether there were significant effects of drug(s) on overall responding that might reflect effects on motor coordination or motivation. These data were analyzed in a manner similar to that for the percentage correct response data.

Pharmacological Magnetic Resonance Imaging

Subjects. Functional imaging studies were performed on male Sprague-Dawley rats (250–350 g; Charles River Laboratories, Como, Italy). Animals had free access to standard rat chow and tap water and were housed in groups of five in solid-bottomed cages with sawdust litter. Room temperature (20–22 °C), relative humidity (45–65%) and dark-light cycles (12-h each, lights on at 6:00 AM) were automatically controlled. After arrival, rats were allowed to acclimate for at least five days. All phMRI studies were conducted in accordance with the Italian laws (DL 116, 1992 Ministero della Sanità, Roma). Animal research protocols were also reviewed and consented to by a local animal care committee, in accordance with the guidelines of the Institute of Laboratory Animal Resources (1996).

Methods for animal preparation/monitoring and MRI acquisition in each phMRI study were similar to methods used in previous studies (Go zzi et al., 2008b). In brief, rats were anesthetized with 3% halothane in a 30:70% O2/N2 gas mixture, tracheotomized, and artificially ventilated with a mechanical respirator to ensure control of blood gas levels. The left femoral artery and vein were cannulated, and the was animal paralyzed with a 0.25 mg/kg i.v. bolus of t-tubocurarine followed by a continuous infusion of 0.25 mg·kg⁻¹·h⁻¹ through the artery. A polyethylene cannula was inserted intraperitoneally or subcutaneously for drug pretreatment. After surgery, the rat was secured into a customized stereotactic holder (Bruker, Ettlingen, Germany), and the halothane level was set to 0.8%. Arterial blood samples (0.5 ml) were taken immediately before and at the end of the functional MRI time series acquisition, and pACO2 and pAO2 were measured using a blood gas analyzer (Supplemental Table 3). All the subjects had pAO2 > 95 mm Hg, corresponding to a hemoglobin saturation greater than 98%. No statistically significant difference (p > 0.05) was observed in mean pre- versus postacquisition pACO2 values for each pair of PCP-challenged groups one-way ANOVA, followed by Fisher’s least significant difference test for multiple comparisons). A magnetic resonance-compatible thermocouple probe was used to measure rectal temperature. The body temperature of all subjects was maintained within physiological range (37 ± 0.8°C) throughout the experiment. Mean arterial blood pressure was monitored continually through the femoral artery. At the end of the experiment, the animals were euthanized with an overdose of anesthetic followed by cervical dislocation.

Relative Cerebral Blood Volume Measurements. MRI data were acquired using a Bruker Avance 4.7-Tesla system, a 72-mm birdcage resonator for radiofrequency pulse transmit, and a Bruker curved “Rat Brain” quadrature receive coil. The MR acquisition for each subject comprised T2-weighted anatomical images using the RARE sequence (Hennig et al., 1986) (effective repetition time (TR,k) = 6000 ms; effective echo time (TE,k) = 110 ms; RARE factor 8; field of view, 40 mm; 256 × 256 × matrix; 16 contiguous 1-mm slices) followed by a time series acquisition with the same spatial coverage and similar parameters (TR,k = 2700 ms, TE,k = 110 ms, RARE factor 32) but with a lower in-plane spatial resolution (128 × 128), giving a functional pixel volume of ~0.1 mm³. The use of T2-weighted images for the time-series acquisition minimized sensitivity both to large blood vessels and inhomogeneities of the static magnetic field (Boxerman et al., 1995) and ensured that the geometry of the time-series images matched the anatomical reference images, facilitating subsequent image analysis. Two successive scans were averaged for a resulting time resolution of 40 s. After five reference images, 2.67 ml/kg ferrous oxide superparamagnetic nanoparticles (Endorem; Guerbet SA, Villepinte, France), a blood pool contrast agent, was injected so that subsequent signal changes would reflect alterations in rCBV. Before the injection of drug pretreatment, an equilibration period of 15 min was allowed. Experiments were performed with intraperitoneal or subcutaneous injection of drug (or vehicle) pre-treatment followed by intravenous PCP challenge (or vehicle) 30 min later. All compounds were injected at a rate of 1 ml/min. The MRI data were acquired over a period of at least 25 min after the administration of the PCP challenge.

Experimental Procedure and Drugs. Phencyclidine hydrochloride (Sigma-Aldrich, Italy), dissolved in saline, was tested at a sub-anesthetic dose (0.5 mg/kg i.v.) that produces robust and reproducible cortico-limbic-thalamic activation (Gozzi et al., 2008b) and elicits substantial behavioral and metabolic (2-deoxyglucose) responses in freely moving rats (Weissman et al., 1987). To allow for a better randomization and to keep the study manageable, GSK2 and GSK3 were tested in separate studies that occurred at different times. Male SD rats were randomly assigned to one of eight groups. GSK2 study groups.

1. Preadministration of vehicle (HPMC 0.5% in water, 4 ml/kg s.c.) followed by challenge with PCP (0.5 mg/kg i.v.) 30 min later (n = 5).
2. Preadministration of GSK2 (30 mg/kg s.c.) followed by i.v. challenge with PCP (0.5 mg/kg i.v.) 30 min later (n = 7).
3. Preadministration of GSK2 (100 mg/kg s.c.) followed by i.v. challenge with PCP (0.5 mg/kg i.v.) 30 min later (n = 7).
4. s.c. Preadministration of vehicle (HPMC 0.5% in water) followed by a challenge with vehicle (saline, 1 ml/rat i.v.) 30 min later (n = 6). This group of rats served as reference (baseline) rCBV baseline for both experiments.

Downloaded from jpet.aspetjournals.org on July 10, 2017
Administration of vehicle, GSK2, GSK3, lamotrigine, or PCP was accompanied by small and transient alterations of mean arterial blood pressure. In all cases, peak magnitude of the mean arterial blood pressure observed (Supplemental Table 6) was within the cerebral blood flow autoregulation range measured under the same anesthetic conditions used in the present study (Gozzi et al., 2007). As we and other groups have shown, positive or negative pharmacologically evoked mean arterial blood pressure changes within the autoregulation range mentioned above do not result in significant central rCBV response when spin-echo MRI sequences are used (Gozzi et al., 2007).

**Neurochemistry**

**Subjects.** Seventy male Sprague-Dawley rats (Charles River Laboratories, originally weighing 225 to 300 g, were housed at 21 ± 1°C with 50% humidity on a 12-h light/dark cycle in accordance with Italian law (art. 7, Legislative Decree 116, 27 January 1992) and the European Communities Council Directives (86/609/EEC).

**Drugs.** GSK2 was dissolved in methylcellulose [0.5% (w/v)] in sterile water. GSK3 was dissolved in methylecellulose [0.5% (w/v) + DMSO (3% (v/v))] in sterile water. PCP (Sigma, Italy) was dissolved in ultra-high-purity water. All injections were made subcutaneously in a volume of 1 ml/kg body weight.

**Experimental Procedures.** Methods were similar to those described elsewhere (Quarta et al., 2009). Subjects were anesthetized and implanted in the mPFC (with respect to bregma: anteroposterior, +5.2 mm; mediolateral, −0.5 mm; and dorsoventral, −1.8 mm). Animals were then returned to their home cages and allowed at least 72 h to recover from the surgery. Twenty-four hours after insertion of the microdialysis probe (MAB4, 4-mm active cuprophane membrane length; Agnthos, Stockholm, Sweden) a Ringer’s solution consisting of 125 mm NaCl, 2.5 mm KCl, 1.18 mm MgCl₂·6H₂O, 1.3 mm CaCl₂·2H₂O, and 2.0 mm NaH₂PO₄ pH 7.4, was pumped through the probe at constant rate of 1.0 μl/min (Univentor 864 Syringe Pump; Agnthos). After a 120-min wash period, three basal 20-min samples were automatically collected (Univentor 820 Microsampler) over 60 min. The animals were then injected with either vehicle, GSK2 (50 or 100 mg/kg s.c.), or GSK3 (30 mg/kg s.c.) followed by PCP (1.5 mg/kg s.c.). Sample collection continued for 3 hours after PCP treatment. All samples were immediately frozen for subsequent analysis.

At the end of all experiments, rats were sacrificed, and brains were collected in 4% formaldehyde solution. Coronal sections were cut to verify probe location. Samples from rats with incorrect probe location were discarded from the final analysis. Monoamine content was measured by reversed-phase high-performance liquid chromatography coupled to an electrochemical detector. Raw data (expressed as picograms per sample, not corrected for probe recovery) were converted to a percentage of baseline values (mean of the samples taken before drug or vehicle administration). Time course data (monoamine levels) were statistically analyzed for each treatment using a two-way ANOVA with a between-subjects factor of drug dose and a repeated-measurements factor of time (Statistica Network 8.0 software; StatSoft, Tulsa, OK). Differences between individual means were assessed with a planned comparison test. Statistical significance was set at p ≤ 0.05 in all cases.

**CNS Side Effect Assessment**

**Subjects.** Male Sprague-Dawley rats were obtained from Charles River Laboratories, weighing 250 to 300 g at test. Rats were housed in groups and left to acclimatize for 1 week under standard laboratory conditions (23 ± 1°C; humidity, 45–65%; lights on 6 AM–6 PM; food and water ad libitum). All tests were performed between 9:00 AM and 2:00 PM. All experiments were performed in accordance with European Community ethical regulations on the care of animals for scientific research (CEE Council 86/609 Italian D.L. 27/01/92 116) and were fully compliant with GSK ethical standards.
Drugs. GSK2 was suspended in HPMC [0.5% (w/v); Colorcon/Dow Chemical Company, Dartford, UK] and Tween 80 [0.1% (v/v); Sigma-Aldrich S.r.l., Milan, Italy]. GSK3 was dissolved in 1 or 3% DMSO (v/v) and then suspended in HPMC [0.5% (w/v)] to the final volume. Lamotrigine (supplied by GSK Medicinal Chemistry) was dissolved in DMSO [0.1% (v/v)] and HPMC [0.5% (w/v)]. All doses and concentrations are expressed in terms of the parent compound.

Procedures. Rat motor behavior was assessed during the light period using automated activity chambers (RXYL-8; Omnetech Instruments, Columbus, OH). Each monitor consisted of a 41 × 41 × 30.5-cm Plexiglas arena covered by a Plexiglas lid with air holes. Each arena was surrounded by two sets of infrared beams for activity measurement, each set consisting of 16 beams located at 2.54-cm intervals around the four sides of the arena. These were located 4.5 cm above the floor for measurement of “horizontal activity” and 15 cm above the floor of the arena for measurement of “vertical activity.” A Digiscan Analyzer (DCM-4; Omnetech Instruments) detected beams broken by the animal and thus determined the location of the rodent within the arena. The main variables recorded by the automated system were horizontal and vertical activity and were expressed as the total number of beam interruptions that occurred in the horizontal/vertical sensors. These variables were measured in 5-min bins across the 30-min session.

Studies were performed according to a blind, randomized design. GSK2 was administered (5 ml/kg body weight p.o.) to rats at doses of 60 (n = 8), 100 (n = 8), and 300 mg/kg (n = 8) 30 min before the test session. GSK3 was administered (2 ml/kg body weight s.c.) to rats at doses of 30, 60, and 100 mg/kg (n = 9 per group) 30 min before the test session. Lamotrigine was given to rats at 3, 10, and 30 mg/kg p.o. (n = 9 per group) 60 min before test session. Control rats (n = 8–9) were given an equal volume of the respective vehicle by the appropriate route at the appropriate time.

Determination of the plasma concentration of each drug was carried out on a subset (n = 6 per group) of the animals used in the behavioral test. Blood samples were taken at 60 min (GSK2 or GSK3) or 90 min (lamotrigine) after drug treatment (at the end of the test period). Blood samples were analyzed for drug concentration using a method based on protein precipitation followed by liquid chromatography/mass spectrometry; plasma concentrations were calculated based on the plasma protein binding for each drug determined from equilibrium dialysis studies (described in Large et al., 2009b), and corrected for the blood/plasma ratio as appropriate.

Data Analysis. Statistical analyses were conducted using GB-Stat v7 (Dynamic Microsoft Systems, Inc., Silver Spring, MD). Behavioral data were analyzed by one-way ANOVA, followed by a one-tailed Dunnett’s post hoc test. Results were expressed as the observed mean ± S.E.M. Differences between groups were considered to be statistically significant if the p value was less than 0.05.

NMDA Receptor Inhibition

Whole-cell patch-clamp recordings were made from rat dissociated cortical neurons (embryonic day 18; maintained in culture for 7–8 days before electrophysiological recordings) voltage-clamped at −60 mV. NMDA receptor-mediated responses were activated by coapplying 50 μM NMDA and 10 μM glycine every 50 s. The extracellular recording solution comprised 130 mM NaCl, 5 mM KCl, 2 mM CaCl2, 30 mM glucose, and 25 mM HEPES (pH adjusted to 7.3 with NaOH) and the intracellular solution comprised 140 mM CsCl, 4 mM MgCl2, 10 mM HEPES, and 10 mM EGTA (pH adjusted to 7.3 with CsOH). Drugs were prepared as 100 mM stocks in DMSO and both preapplied in extracellular solution and coapplied with NMDA and glycine.

Monoamine Oxidase Inhibition

Brain Homogenate Preparations. Adult male CD rats (250–300 g, Charles River, Italy) were used to prepare forebrain homogenate as reported previously (Southam et al., 2005). Animals were killed by decapitation and forebrains were quickly removed and placed in ice-cold 154 mM sodium phosphate buffer, pH 7.8. Tissues were homogenized using an Ultra-Turrax T8 homogenizer (IKA-Werke GmbH & Co. KG, Staufen, Germany) and then centrifuged at 2000g for 10 min at 4°C. The supernatant was rapidly frozen in dry ice and kept at −80°C until use. Protein concentration was measured using a Protein Assay Kit (Bio-Rad Laboratories S.r.l., Segrate, Italy).

In Vivo Rat Treatment for Ex Vivo Studies. Adult male CD rats (250–300 g, 4–5 per group; Charles River Laboratories) were used. GSK2 was administered (2 ml/kg body weight) at 0.3, 3, and 10 mg/kg s.c. in 0.5% (w/v) methycellulose in water in a first experiment, and at 3, 10, and 30 mg/kg s.c. in 1% (v/v) DMSO/0.5% (w/v) methycellulose in water in a second experiment. In both experiments, vehicle was administered to control rats. Thirty minutes or 24 h after treatment, rats were killed by decapitation, the forebrains were removed, and homogenates were prepared as above.

Drugs and Materials. Clorgyline and l-deprenyl were obtained from Sigma-Aldrich. [14C]benzylamine (specific activity, 2.00 GBq/ mmol) was from GE Healthcare Italia (Milan, Italy) and [3H]5-hydroxytryptamine creatine sulfate (specific activity, 1.11 or 0.7511 TBq/mmol) was from Perkin Elmer Italia S.P.A. (Milan, Italy). The Amplex Red Monoamine Oxidase Assay Kit and Amplex Red substrate were from Invitrogen (Carlsbad, CA). Recombinant human MAO-A and MAO-B were obtained from Sigma-Aldrich Quimica SA (Madrid Spain).

MAO-A and MAO-B Assays

MAO-A and MAO-B activities using human recombinant enzymes were assayed by measuring hydrogen peroxide (H₂O₂), the coproduct produced during the deamination of substrate. In the presence of excess N-acetyl-L-3,4-dihydroxyphenoxazone (Amplex Red; Invitrogen) and horseradish peroxidase, each molecule of peroxide produces one molecule of Amplex Red into the stable fluorescent product resorufin. Assays were performed in duplicate or triplicate in a final volume of 10 μl using black 384-well plates containing 0.23 IU/ml human MAO-B or 0.28 IU/ml human MAO-A recombinant enzymes and incubated for 1 h at room temperature in the dark. For the MAO-B assay, the substrate was 400 μM benzylamine and for MAO-A the substrate was 200 μM p-tyramine. 50 μM Amplex Red and 1 IU/ml commercial horseradish peroxidase in 50 mM potassium phosphate buffer at pH 7.4 were added to the plates with the appropriate substrate and test compound. Reaction was started by the addition of the enzymes, and fluorescence was measured after 60 min in the dark using a fluorescent plate reader with excitation and emission filters at 555 nm and 590 nm, respectively. MAO-A and MAO-B activities were expressed as a percentage of inhibition.

Native MAO assays were performed in triplicate in a final volume of 100 μl of phosphate-buffered saline (pH 7.4; Invitrogen) containing 0.05 mg of protein (rat forebrain homogenates) and incubated at 37°C for 10 min as described previously (Southam et al., 2005). For the MAO-A assay, the substrate was 5 μM [3H]5-HT; for MAO-B, the substrate was 13.5 μM [14C]benzylamine. MAO-A or -B isosform activity was pharmacologically isolated by inclusion in the reaction mix of 1 μM l-deprenyl or 1 μM clorgyline, respectively. Assays were terminated by the addition of 2 M HCl, and deaminated reaction products were extracted by mixing with 600 μl of 1:1 (v/v) ethyl acetate/toluene. Samples were centrifuged at 8000g for 2 min at room temperature; in duplicate, 200 μl of solvent phase was added to 3.5 ml of scintillation fluid, and radioactivity was determined by β-counter scintillation counting. Nonspecific activity was determined by adding HCl before the forebrain homogenate. The amount of MAO-A and MAO-B activity was expressed as nanomoles per milligram of protein per minute for substrate dependence in vitro determinations and ex vivo experiments and as percentage of control activity for in vitro concentration inhibition determinations.

Data Analysis. Vmax and Km parameters were obtained from in vitro substrate concentration-dependence curves using a nonlinear
regression fit to the Michaelis-Menten equation (Prism version 4; GraphPad Software, San Diego, CA). pIC50 values were calculated from in vitro concentration inhibition curves using nonlinear regression fit to a sigmoidal dose-response curve (Prism version 4). pKi values were calculated from IC50 values using the Cheng and Prusoff (1973) equation and calculated Km values from in vitro substrate concentration-dependence curves. Statistical analysis was conducted using Prism (version 4). Data derived from ex vivo studies on MAO activity were analyzed by one-way ANOVA, followed by a Dunnett’s post hoc test. Differences between groups were considered to be statistically significant if the p value was less than 0.05.

Results

Reversal Learning

Experiment 1. A one-way ANOVA of the experiment indicated that there was no significant effect of PCP or GSK2 treatment on correct responding in the initial phase (F5,97 = 0.41, not significant). However, a one way ANOVA showed that there was a significant effect of drug treatment on correct responding in the reversal phase (F5,97 = 9.6, p < 0.001), such that animals showed a significant difference in correct responses between drug treatment groups (Fig. 1A). Post hoc analysis showed that PCP alone significantly reduced correct responding in the reversal phase (p < 0.001) compared with vehicle. GSK2 (20–80 mg/kg p.o.) dose-dependently attenuated the deficit in reversal learning induced by PCP. This reduction was significantly attenuated by GSK2 at 60 mg/kg and at 80 mg/kg (p < 0.05 and p < 0.001, respectively) compared with PCP alone. Neither PCP alone nor GSK2 at 20–80 mg/kg plus PCP had a significant effect on the total number of lever presses in either the initial or reversal phases of the task [F5,97 = 0.85 (not significant) or 0.94 (not significant), respectively] (Supplemental Table 2). Furthermore, GSK2 had no effect alone on either the initial or reversal phase of the task or on lever pressing (Supplemental Fig. 1; Supplemental Table 1).

Experiment 2. A one-way ANOVA of the experiment indicated that PCP or GSK3 treatment had no significant effect on correct responding in the initial phase (F4,49 = 0.98, not significant). However, a one-way ANOVA revealed a significant effect of drug treatment on correct responding in the reversal phase (F4,49 = 4.0, p < 0.01), such that animals showed a significant difference in correct responses between drug treatment groups (Fig. 1B). Post hoc analysis showed...
that PCP alone significantly reduced correct responding in the reversal phase ($p < 0.01$) compared with vehicle. GSK3 (10–60 mg/kg p.o.) dose-dependently reduced the deficit produced by PCP with a significant reduction in the deficit at 30 and 60 mg/kg ($p < 0.05$ and $p < 0.01$, respectively). Neither PCP alone nor GSK3 with PCP significantly affected lever pressing in the initial or reversal phases of the task [$F_{4,49} = 1.8$ (not significant) or 1.9 (not significant)] (Supplemental Table 4). Furthermore, GSK3 had no effect alone on either the initial or reversal phases of the task or on lever pressing (Supplemental Fig. 2; Supplemental Table 3).

**Experiment 3.** In a final experiment, conducted with the same groups of rats, a single dose of lamotrigine (25 mg/kg p.o.) was tested. A one-way ANOVA of the experiment indicated that there was no significant effect of PCP or lamotrigine treatment on correct responding in the initial phase ($F_{3,39} = 0.38$, not significant). However, a one-way ANOVA revealed a significant effect of drug treatment on correct responding in the reversal phase ($F_{3,39} = 3.9, p < 0.05$). As expected, lamotrigine significantly prevented the deficit induced by PCP in the reversal phase of the task ($p < 0.05$) (Fig. 1C). Lamotrigine alone or with PCP did not significantly affect lever pressing (Supplemental Table 5). Furthermore, lamotrigine alone had no effect on either the initial or reversal phases of the task or on lever pressing.

**Functional Neuroimaging**

PCP administration (groups 1 and 5) produced a robust and sustained rCBV response in cortical (prefrontal, orbitofrontal, cingulate/retrosplenial cortices) and subcortical (frontal regions of the caudate putamen, nucleus accumbens, ventromedial and dorsolateral thalamus, ventral hippocampus) structures (Fig. 2). The overall temporal profile of PCP-induced activation was comparable in all the activated regions, with a sustained response that lasted throughout the 25-min period examined (Supplemental Figs. 3–5). Despite differences in the peak magnitude of PCP response across studies, the spatial distribution and relative amplitudes of the regional response to PCP were consistent and conserved across the different control groups (groups 1 and 5; Fig. 3).

![Fig. 2](https://i.imgur.com/3z5Q5Q.png)
Fig. 3. Magnitude of mean rCBV response (AUC_{4–20min}) to PCP in representative anatomical volumes of interest. A, left, Veh-PCP (group 5); GSK2 30 mg/kg PCP (group 6). Right, Veh-PCP (group 5); GSK2 100 mg/kg PCP (group 7). | \[ p < 0.05; \] \[ p < 0.01 \] versus Veh-PCP (groups 5), one-way ANOVA followed by Dunnett’s test for multiple comparison. B, left, Veh-PCP (group 1); GSK3 10 mg/kg PCP (group 2). Middle, Veh-PCP (group 1); GSK3 30 mg/kg PCP (group 3). Right, Veh-PCP (group 1); lamotrigine 10 mg/kg PCP (group 4). | \[ p < 0.05; \] \[ p < 0.01 \] versus Veh-PCP (groups 1), one-way ANOVA followed by Dunnett’s test for multiple comparison. Acb, nucleus accumbens; B. ganglia, basal ganglia; Cpu, caudate putamen; DL, dorsolateral thalamus; VM, ventromedial thalamus; AD, antero dorsal hippocampus; V, ventral hippocampus; PDG, posterior dentate gyrus; PD, posterodorsal hippocampus; S1, primary somatosensory cortex; V1, primary visual cortex; Cg, cingulate cortex; PFC, medial prefrontal cortex.

---

<table>
<thead>
<tr>
<th>Structure</th>
<th>Veh + PCP</th>
<th>GSK2 (30 mg/kg) + PCP</th>
<th>GSK2 (100 mg/kg) + PCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cpu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortex</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Structure</th>
<th>Veh + PCP</th>
<th>GSK3 (10 mg/kg) + PCP</th>
<th>GSK3 (30 mg/kg) + PCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cpu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortex</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---
Pretreatment with GSK2 (30 or 100 mg/kg s.c.) produced a dose-dependent reduction in the rCBV response to PCP with near-complete response inhibition at the highest dose (Figs. 2A). These effects were also evident on rCBV time-course plots (Supplemental Fig. 3). No areas of increased response to PCP were observed in any of the GSK2-pretreated groups.

Pretreatment with GSK3 (10 or 30 mg/kg i.p.) produced a dose-dependent reduction in the rCBV response to PCP with near-complete response inhibition at the highest dose (Fig. 2B; Supplemental Fig. 4). These effects were also evident from the VOI-based analysis (Fig. 3B). Pretreatment with lamotrigine (10 mg/kg i.p.) also produced a profound inhibition of PCP-induced activation (Fig. 2B; Supplemental Fig. 5) that was evident in both the activation maps and VOI-based analysis (Fig. 3B).

Preadministration of GSK2, GSK3, lamotrigine, or vehicle per se did not produce substantial alterations of basal rCBV with respect to vehicle in any of the regions examined (Supplemental Figs. 6–8). This finding rules out a "ceiling" or "floor" rCBV effects in the response inhibition produced by the pretreatments.

**Neurochemistry**

GSK2 (50–100 mg/kg s.c.) had no effect on extracellular levels of either NA, DA, or 5-HT in the mPFC in the 60-min period before administration of 1.5 mg/kg s.c. PCP ($F_{3,17} = 2.38$, $F_{3,22} = 2.91$, or $F_{3,20} = 0.21$, respectively, all nonsignificant). Systemic administration of PCP induced an increase in the extracellular levels of all monoamines, although this was significant over the full time course only for NA in this experiment (Fig. 4A). Consistent with this, a two-way ANOVA applied to the post-treatment NA values showed a significant effect of treatment ($F_{3,17} = 13.83$, $p < 0.01$), as well as time ($F_{8,136} = 6.48$, $p < 0.01$). A two-way ANOVA applied to the post-treatment DA values showed a significant effect of time ($F_{8,170} = 16.22$, $p < 0.01$) but not treatment, although there was a time-by-treatment interaction ($F_{24,176} = 1.62$, $p < 0.05$), consistent with an increase in DA levels due to PCP that was relatively transient, as can be appreciated from Fig. 4B. In contrast, a two-way ANOVA applied to the post-treatment 5-HT values showed only a significant effect of time ($F_{8,160} = 4.68$, $p < 0.01$), although the increase at specific time points was close to significance ($p = 0.09$). Comparisons between the vehicle + vehicle groups and drug-treatment groups were conducted using a multiple comparison test at each time point, with significant differences indicated by the stars in Fig. 4. A similar comparison of the vehicle + PCP groups with the GSK2-treated groups found no significant differences, suggesting no effect of GSK2 on PCP-induced increases in monoamine levels.

GSK3 (30 mg/kg s.c.) had no effect on extracellular levels of either NA, DA, or 5-HT in the mPFC in the 40-min period before administration of 1.5 mg/kg s.c. PCP ($F_{2,18} = 1.44$, $F_{2,21} = 0.14$, or $F_{2,19} = 0.46$, respectively, all nonsignificant). In this experiment, systemic administration of PCP induced a significant increase in the extracellular levels of all monoamines in the rat mPFC (Fig. 5). A two-way ANOVA applied to the post-treatment NA values showed a significant effect of treatment ($F_{2,18} = 8.71$, $p < 0.01$) and time ($F_{2,144} = 7.35$, $p < 0.01$), as well as a time-by-treatment interaction ($F_{8,144} = 1.92$, $p < 0.05$). Two-way ANOVA applied to the post-treatment DA values showed a significant effect of treatment ($F_{2,21} = 4.74$, $p < 0.05$) and time ($F_{8,160} = 5.47$, $p < 0.01$). Two-way ANOVA applied to the post-treatment 5-HT values also showed a significant effect of treatment ($F_{2,19} = 3.59$, $p < 0.05$) and time ($F_{8,160} = 5.47$, $p < 0.01$).
p < 0.05) and time (F8,152 = 2.60 p < 0.01), as well as a time-by-treatment interaction (F16,152 = 2.60, p < 0.01). The significance of comparisons between the vehicle + vehicle groups and drug-treated groups at each time point are indicated in Fig. 5. Comparisons of the vehicle + PCP group and the GSK3-treated group found no differences.

Motor Behavior
One-way ANOVA revealed that there was a statistically significant effect of GSK2 treatment on vertical activity (F3,32 = 5.5, p < 0.01), the two highest doses of the drug (100 and 300 mg/kg p.o.) significantly reducing activity compared with vehicle-treated rats (p < 0.05 and p < 0.01, respectively; Fig. 6A). A similar trend toward a reduction was also observed in horizontal activity after treatment (F3,32 = 3.4, p < 0.05); however, the reduction was statistically significant compared with vehicle-treated rats only at the highest dose (p < 0.05; Fig. 6A). At 60 mg/kg, the highest dose that did not significantly affect either horizontal or vertical activity, the free plasma concentration of GSK2 was 786 ng/ml (total blood, 7863 ng/ml; the blood/plasma ratio was 0.6 and plasma protein binding was 94%) (Table 1).

GSK3 significantly reduced vertical activity (F3,32 = 5.75, p < 0.01) at all doses tested (30, 60, and 100 mg/kg s.c.; p < 0.05, p < 0.01, and p < 0.01 versus vehicle, respectively; Fig. 6B). The effect of treatment on horizontal activity was marginally significant (F3,32 = 2.3, p < 0.10); post hoc analysis showed that animals treated with the highest dose of GSK3 (100 mg/kg s.c.) had a lower horizontal activity than vehicle-treated rats (p < 0.05; Fig. 6B). The mean free plasma concentration of GSK3 at the lowest dose tested, 30 mg/kg s.c., was 325 ng/ml (total blood, 6509 ng/ml; the blood/plasma ratio was 0.62 and plasma protein binding was 96.9%) (Table 1).

Lamotrigine significantly reduced vertical activity (F3,32 = 3.04, p < 0.05) at all doses tested (p < 0.05 versus veh) but had no effect on horizontal activity at any dose (F3,32 = 1.26, p = 0.31) (Fig. 6C). The dose of 3 mg/kg was associated with a plasma concentration of 675 ng/ml (total blood, 1377 ng/ml; the blood/plasma ratio was 0.62 and plasma protein binding was 51%) (Table 1).

NMDA Receptor Antagonism
The application of GSK2 (100 μM) to dissociated rat cortical neurons inhibited whole-cell currents mediated by NMDA receptor activation. Mean current amplitude was reduced by 29 ± 4% (n = 5; Supplemental Fig. 9a). Likewise, the application of GSK3 (100 μM) inhibited whole-cell NMDA receptor-mediated currents by 20 ± 4% (n = 4; Supplemental Fig. 9b).

Monoamine Oxidase Inhibition
Initial studies with human recombinant MAO-A and -B showed that GSK2 was a potent inhibitor of human MAO-B (pIC50 = 7.96 ± 0.12, n = 4) but did not inhibit human MAO-A (pIC50 = 4.39 ± 0.03, n = 3). In contrast, GSK3 had no activity at either enzyme (pIC50 < 4, n = 2 in each case). No further studies were conducted with GSK3. The ability of GSK2 to inhibit MAO-A and MAO-B activity in rat forebrain homogenate was assayed using [3H]5-HT (in the presence of 1 μM selegiline) and [14C]benzylamine (in the presence of 1 μM clorgyline), respectively.

Substrate dependence of MAO activity was first determined, giving Kma values of 75.9 ± 4.71 and 93.2 ± 8.3 μM at MAO-A and -B, respectively (n = 3), and velocity values (Vmax) of 1.106 ± 0.05 and 0.831 ± 0.07 nmol · mg⁻¹ · min⁻¹, respectively (n = 3). GSK2 inhibited rat forebrain MAO-B with a pKᵢ of 7.20 ± 0.09 (n = 3), similar to that of the standard inhibitor 1-deprenyl (pKᵢ, 7.15 ± 0.08; n = 3). In
contrast, GSK2 displayed low affinity for MAO-A enzyme in rat brain homogenate (pKᵢ, <5; n = 3), whereas the selective inhibitor clorgyline showed the expected affinity (pKᵢ, 7.6; n = 2).

Given the activity of GSK2 versus MAO-B, further studies evaluated the potency of the drug to inhibit the enzyme in vivo. GSK2 significantly inhibited rat forebrain MAO-B activity, ex vivo, at all doses tested (p < 0.05 using repeated-measures ANOVA analysis with post hoc Dunnett’s testing) 30 min after treatment (Tₗmax) (Fig. 7). The highest dose of GSK2 (30 mg/kg s.c.) resulted in MAO-B enzyme inhibition of 65% (0.039 ± 0.004 versus 0.013 ± 0.002 nmol · mg⁻¹ · min⁻¹, vehicle versus 30 mg/kg-treated animals). Twenty-four hours after dosing with GSK2 (3 mg/kg s.c.), MAO-B enzyme activity in rat forebrain was comparable with that in vehicle-treated animals (0.045 ± 0.009 versus 0.048 ± 0.004 nmol · mg⁻¹ · min⁻¹, vehicle versus 3 mg/kg-treated animals). GSK2 did not inhibit MAO-A activity in rat brain homogenate, ex vivo, at any dose tested (data not shown).

Discussion

We investigated the ability of two novel use-dependent sodium channel blockers, GSK2 and GSK3, to prevent a cognitive deficit induced in rodents by the NMDA receptor antagonist PCP. Results from the reversal learning model showed that, like lamotrigine (Idris et al., 2005), both GSK2 and GSK3 attenuated PCP disruption of the cognitive task. We have shown previously that atypical antipsychotic agents could attenuate the deficit produced by PCP, whereas traditional antipsychotics did not (Idris et al., 2005). These findings suggest that GSK2 and GSK3, like lamotrigine, have similarities to atypical antipsychotic agents in this regard. Low doses of PCP and ketamine are thought to produce psychotomimetic effects through selective blockade of NMDA receptor located on inhibitory interneurons within the cortex (for review, see Large, 2007). Thus, reduced local circuit inhibition may lead to an increase in excitability and a decrease in firing precision of principal glutamatergic neurons. In support of this, ketamine has been shown to increase glutamate release in the cortex (Moghaddam et al., 1997) and alter the firing pattern of cortical projection neurons (Jackson et al., 2004). It has been hypothesized that the efficacy of lamotrigine in models of aberrant behavior induced by PCP or ketamine is most likely due to sodium channel inhibition, which can normalize the activity of glutamatergic neurons in the cortex (Large et al., 2005). The results of the present study with GSK2 and GSK3, two structurally unrelated sodium channel blockers, are consistent with this hypothesis.

Lamotrigine was effective in the reversal-learning model at plasma concentrations that were 3.7-fold higher than those required for anticonvulsant efficacy (Table 1; Large et al., 2009b). Likewise, GSK3 required plasma concentrations approximately 4-fold higher than those producing a significant anticonvulsant effect; GSK2, however, required more than 14-fold higher plasma concentrations for efficacy in the reversal-learning model compared with the electroshock model (Table 1; Large et al., 2009b). The active plasma concentrations quoted for the reversal-learning model (Table 1) are based on estimates from separate pharmacokinetic studies in rat using the appropriate route of administration for each drug. Given the variability typical of such measures across studies, it will be necessary to confirm these concentrations in a dedicated pharmacokinetic analysis in the reversal-learning model. However, given the consistent increase in required plasma concentration for each of the three drugs, it seems likely that prevention of the PCP-induced cognitive deficit does require higher levels of the sodium channel blocking drugs compared with their anticonvulsant potency. We showed previously that the anticonvulsant potency of the three drugs in the electroshock seizure model was consistent with their in vitro sodium channel affinities (Table 1; Large et al., 2009b), taking into account their respective plasma protein and brain tissue binding. We suggest that a similar relationship might hold for the reversal-learning model, albeit at higher drug levels, for lamotrigine and GSK3. However, in the case of GSK2, the much greater increase in plasma concentration required for efficacy in the reversal-learning model compared with the drugs anticonvulsant potency suggests that other factors may be involved.

To shed further light on these possible differences, we profiled GSK2, GSK3, and lamotrigine in a series of mechanistic studies. For practical reasons, it was not always possible to use identical routes of drug administration for the different in vivo studies. However, we used prior pharmacokinetic data to select doses that would achieve comparable exposures or else we used at least two doses in each model to ensure that we covered a sufficient range of exposure to draw conclusions regarding efficacy. We used phMRI to profile the brain-wide hemodynamic response to a short-term challenge with PCP to look for regional effects that might be associated with the reversal-learning results. The pattern of activation produced by PCP was consistent with that observed in our
previous studies (Gozzi et al., 2008a) and similar to the pattern of 
\(^{14}\text{C}\)2-deoxyglucose uptake induced by NMDA receptor antagonists (Duncan et al., 1999). A significant increase in hemodynamic activity in frontal cortical areas is consistent with the impact of PCP on cognitive function in the reversal-learning task. These experiments confirm our previous finding that lamotrigine can fully inhibit the central hemodynamic response to a psychotomimetic dose of PCP (Gozzi et al., 2008a). GSK2 and GSK3 were also able to fully prevent the functional activation elicited by PCP, with a similar brain-wide pattern of inhibition. This brain-wide pattern of inhibition contrasts with that of the atypical antipsychotics tested in this model: clozapine, for example, produced a greater inhibition of thalamic activation, with less effect on cortical PCP-induced activation (Gozzi et al., 2008a). Brain-wide inhibition of the PCP-induced response suggests that the point of intervention of the sodium channel blockers is closer to the site of action of PCP compared with the antipsychotic drugs. However, this also raises the concern that the drugs might simply interfere with PCP inhibition of NMDA receptors. We have previously shown that neither GSK2 nor GSK3 displaces binding of a competitive NMDA receptor antagonist, \(\text{D,L-(E)-2-amino-4-propyl-5-phosphono-3-pen}
\)tenoic acid (CGP39653), to adult rat cortical homogenates (\(<10\%\) inhibition of specific binding at 10 \(\mu\text{M}\) concentrations of each compound). In the present study, we used an electrophysiological assay to show that neither GSK2 nor GSK3 inhibits NMDA receptor-mediated currents in cultured cortical neurons. A caveat to these functional studies is that the NMDA receptor subunit composition of the embryonic cortical neurons differs from the adult; thus, we cannot rule out the possibility that GSK2 and -3 might have a greater effect on NR2A subunits that are predominant in the adult, compared with the NR2B subunits that are predominant in our test system. However, given that only a small reduction (\(<30\%\)) in NMDA currents was observed in the cortical neuron preparation in the presence of concentrations of GSK2 or GSK3 nearly 100-fold higher than those required for efficacy in the behavioral model, we conclude that direct interaction with NMDA receptors is unlikely to account for their in vivo efficacy.

In contrast to the similarities in efficacy of the two new drugs compared with lamotrigine in the reversal-learning and phMRI studies, there were differences when comparing the ability of the drugs to prevent PCP-induced neurochemical changes in frontal cortex. Lamotrigine significantly reduced PCP-induced overflow of DA and 5-HT, with a strong trend to reduce NA levels, but had no effect on locomotor hyperactivity (Quarta and Large, 2010). Neither GSK2 nor GSK3 significantly reduced the PCP-induced increase in any of the monoamines (comparing vehicle + PCP to GSK + PCP groups), although with GSK3, there was perhaps a trend for a reduction in NA and DA. The absence of significant effects of the new compounds on PCP-induced monoamine overflow compared with lamotrigine could be due to variability in the response to the psychotomimetic. For example, the increase in serotonin in the first experiment (Fig. 4C) was less robust compared with the second (Fig. 5C). However, the monoamine increases observed in both of the present experiments were numerically similar to those observed in the previous lamotrigine study (Quarta and Large, 2010). Insufficient doses of GSK2 or GSK3 relative to lamotrigine also seem unlikely, because the subcutaneous doses chosen would achieve higher exposures than the oral doses that were effective in the reversal learning model. Thus, these results suggest that, whereas the new sodium channel blockers robustly prevent disruption of PCP-induced reversal learning
and regional metabolic activation, PCP-induced monoamine overflow is at best only weakly blocked. A dissociation between locomotor hyperactivity and increased cortical monoamine levels induced by NMDA receptor antagonists has been shown previously (Adams and Moghaddam, 1998). Our studies now suggest an extension of this dissociation to include the cognitive disruption caused by NMDA receptor antagonists. The absence of effect of GSK2 and GSK3 also suggests that PCP-induced monoamine overflow is less sensitive to sodium channel blockade than the other consequences of NMDA receptor antagonism. We can speculate that PCP-induced monoamine overflow is driven by effects of the psychotomimetic directly within brainstem monoamine nuclei and not as a consequence of increased glutamate release from cortical afferents to these areas (see Fig. 2 in Large, 2007). However, given the contrasting result from our earlier study, which found that lamotrigine could significantly reduce PCP-induced increases in at least DA and 5-HT (Quarta and Large, 2010), further evaluation of this aspect of NMDA receptor antagonist models is required.

Given the higher fold increase in concentration of GSK2 required for efficacy in the reversal learning model compared with GSK3 and lamotrigine, we wondered whether interaction of GSK2 with monoamine oxidase B might be a factor, because lamotrigine (Southam et al., 2005) and GSK3 (data not shown) have little or no interaction with this enzyme. GSK2, at doses below those that were effective in the reversal-learning model, significantly inhibited MAO-B activity in vivo; therefore, we can assume that significant inhibition of the enzyme will have occurred at the doses used in the reversal-learning model, phMRI, and neurochemical studies. The drug alone did not affect monoamine levels in the neurochemistry study; however, this would be consistent with previous studies with other MAO-B inhibitors (e.g., Lamensdorf et al., 1996). The physiological role of MAO-B in the CNS is less well studied than MAO-A (partly because of the absence of very selective inhibitors), although MAO-B inhibitors, such as rasagiline, have been progressed for adjunctive treatment of Parkinson’s disease (Hauser, 2009), suggesting some effect on dopamine disposition with chronic dosing. We can speculate that interaction with MAO-B might account for the quantitative difference in the efficacy of GSK2 with respect to GSK3 and lamotrigine in the reversal-learning model. However, the mechanism by which acute MAO-B inhibition might reduce the efficacy of the sodium channel blocker in this test is unclear.

A final aim of the present study was to assess the potential of the new sodium channel blockers to produce centrally mediated side effects typical of their class (for example, sedation, muscle relaxation, and motor incoordination) (Upton et al., 1997). The measurement of an animal’s basal activity in a novel environment allows the assessment of these adverse effects (Helton et al., 1998). In the present study, all three drugs affected vertical activity at lower doses than those that impaired horizontal activity. Vertical activity mainly consists of the animal rearing, and is likely to be a purely exploratory behavior; it may also require greater muscle strength and coordination and thus may be more sensitive to sedative or ataxic effects of drugs than the general locomotion that contributes to horizontal activity measures. Consistent with this, each of the three drugs produced a significant impairment of vertical activity at lower doses than those that impaired horizontal activity. The profile of impairment for GSK2 and GSK3 was similar to that of lamotrigine and consistent with their sodium channel-blocking mechanism. As discussed earlier, each drug required a higher plasma concentration for significant efficacy in the reversal-learning model compared with the electroshock seizure model. On the basis of estimates of plasma concentrations required for efficacy compared with the measured plasma concentrations associated with motor impairment (Table 1), the therapeutic index for these drugs in patients with schizophrenia may be lower than for patients with epilepsy. However, it should be noted that no impairment of motor behavior (lever pressing) was observed with any dose of the three drugs in the reversal learning study itself.

In conclusion, we have shown that the two novel sodium channel blockers have similar qualitative efficacy to lamotrigine in preventing the cognitive deficits produced by the NMDA receptor antagonist, PCP, in a reversal learning task in rats. These results support the evaluation of sodium channel blockers in the treatment of cognitive dysfunction in patients with schizophrenia; however, higher doses than those required for anticonvulsant efficacy may be needed, with a consequently higher risk of mechanism-dependent central side effects.

Acknowledgments

We thank Dr. Adam Schwarz for assistance with the phMRI studies, Dr. Gael Hedou and Riccardo Renzi for assistance with the microdialysis experiments, and Beatriz Rodriguez for the recombinant MAO assays. We also thank Simon Tate and Convergence Pharmaceuticals for permission to publish these results and for helpful comments on the manuscript.

Authorship Contributions

Participated in research design: Large, Read, Gozzi, Gill, Gunthorpe, Neill, and Alvaro.

Conducted experiments: Bison, Sartori, Gozzi, Quarta, Antolini, Hollands, Gill, and Idris.
Contributed new reagents or analytic tools: Alvaro.
Performed data analysis: Large, Bison, Quarta, Gozzi, Antolini, Hollands, Gill, and Idris.
Wrote or contributed to the writing of the manuscript: Large, Gozzi, Quarta, Gunthorpe, and Neill.

References

Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108.
Large CH (2007) Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacology 21:283–301.

Address correspondence to: Dr. Charles H. Large, Medicines Research Centre, Via Fleming 4, Verona 37135, Italy. E-mail: charles.large@autofany.org